ReviewOpen respiratory archives2027
Future Treatments for Tobacco Dependence.
Review in Open respiratory archives, 2027. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Scientific evidence supports that the combination of psychological counseling and pharmacological treatment is the most effective healthcare intervention to help smokers quit. Four types of medications have been shown to be safe and effective: nicotine replacement therapy (NRT), bupropion, varenicline, and cytisinicline. Nevertheless, based on the results of new studies, we can point out several opportunities for development clinical research in this field: (a) finding the most effective doses for cytisinicline, (b) finding the effectiveness and safety of cytisinicline in smokers with chronic disorders, (c) comparing the effectiveness and safety of cytisinicline at higher doses with varenicline at standard doses, (d) investigating the effectiveness and safety of varenicline and cytisinicline used at standard doses but in different pharmaceutical formulations, (e) comparing the effectiveness and safety of cytisinicline at higher doses with nicotine replacement combined treatment, (f) determining the effectiveness and safety of smoking cessation medications as a treatment for new tobacco and nicotine products users (electronic cigarettes and heated tobacco users), (g) to determine the effectiveness and safety of combining pharmacological treatment for smoking cessation with non-invasive brain stimulation, and (h) to optimize the efficacy and safety of smoking cessation medications based on nicotine metabolite ratio (NMR) and probably the most recent suggestion to determine the efficacy and safety of glucagon-like peptide-1 (GLP-1) receptor agonists. All these aspects will be discussed in this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.